Organogenesis Holdings Full Year 2023 Earnings: Misses Expectations
Organogenesis Holdings (NASDAQ:ORGO) Full Year 2023 Results
Key Financial Results
Revenue: US$433.1m (down 3.9% from FY 2022).
Net income: US$4.95m (down 68% from FY 2022).
Profit margin: 1.1% (down from 3.4% in FY 2022). The decrease in margin was driven by lower revenue.
EPS: US$0.038 (down from US$0.12 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Organogenesis Holdings Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 16% from a week ago.
Risk Analysis
We should say that we've discovered 4 warning signs for Organogenesis Holdings (1 makes us a bit uncomfortable!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
